Detalles de la búsqueda
1.
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.
N Engl J Med
; 2024 Jun 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-38924756
2.
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.
N Engl J Med
; 389(21): 1935-1948, 2023 Nov 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-37937763
3.
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
N Engl J Med
; 383(10): 931-943, 2020 09 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32469185
4.
Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.
BMC Cancer
; 22(1): 625, 2022 Jun 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35672677
5.
Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer.
Future Oncol
; 17(8): 965-977, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33242257
6.
EGFR tyrosine kinase inhibitors for EGFR mutation-positive non-small-cell lung cancer: outcomes in Asian populations.
Future Oncol
; 17(18): 2395-2408, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33855865
7.
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study.
Future Oncol
; 16(34): 2799-2808, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32854536
8.
Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies.
Cancer
; 125(6): 892-901, 2019 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30512189
9.
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study.
Future Oncol
; 15(25): 2905-2914, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31370698
10.
Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer.
Future Oncol
; 15(20): 2371-2383, 2019 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-31354046
11.
Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study.
Future Oncol
; 14(27): 2861-2874, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-30336693
12.
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.
Lancet Oncol
; 16(7): 830-8, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26051236
13.
Recommended first-line management of asymptomatic brain metastases from EGFR mutant and ALK positive non-small cell lung cancer varies significantly according to specialty: an international survey of clinical practice.
J Thorac Dis
; 15(8): 4367-4378, 2023 Aug 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-37691657
14.
Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial.
JAMA Oncol
; 9(9): 1260-1266, 2023 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37270698
15.
Recommended first-line management of brain metastases from melanoma: A multicenter survey of clinical practice.
Radiother Oncol
; 168: 89-94, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35121033
16.
Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study.
Clin Lung Cancer
; 23(8): 720-730, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36038416
17.
Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study.
Eur J Cancer
; 172: 276-286, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35810553
18.
Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial.
Lung Cancer
; 154: 92-98, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33636453
19.
Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial.
J Thorac Oncol
; 16(8): 1369-1378, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33845211
20.
Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.
J Thorac Oncol
; 16(12): 2091-2108, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34537440